about
Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.Exploiting virus-like particles as innovative vaccines against emerging viral infectionsImmunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.Phage display creates innovative applications to combat hepatitis B virusSilica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.Towards a novel influenza vaccine: engineering of hemagglutinin on a platform of adenovirus dodecahedron.A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice.Involvement of ESCRT-II in hepatitis B virus morphogenesis.Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteinsCryo-EM study of Hepatitis B virus core antigen capsids decorated with antibodies from a human patient.Whole-Chain Tick Saliva Proteins Presented on Hepatitis B Virus Capsid-Like Particles Induce High-Titered Antibodies with Neutralizing PotentialThe Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.Exploring the induction of preproinsulin-specific Foxp3(+) CD4(+) Treg cells that inhibit CD8(+) T cell-mediated autoimmune diabetes by DNA vaccinationEngineering virus-like particles as vaccine platformsTargeted immunomodulation using antigen-conjugated nanoparticles.Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice.Bioengineering virus-like particles as vaccines.Chronic hepatitis B: A wave of new therapies on the horizon.SplitCore: an exceptionally versatile viral nanoparticle for native whole protein display regardless of 3D structure.An N-terminal extension to the hepatitis B virus core protein forms a poorly ordered trimeric spike in assembled virus-like particles.Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies.SplitCore Technology Allows Efficient Production of Virus-Like Particles Presenting a Receptor-Contacting Epitope of Human IgE.Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide.Delivery of chimeric hepatitis B core particles into liver cells.Cationic domains in particle-forming and assembly-deficient HBV core antigens capture mammalian RNA that stimulates Th1-biased antibody responses by DNA vaccinationPlasmid dimerization increases the production of hepatitis B core particles in E. coli
P2860
Q27308848-F44282B0-D4EE-47C9-82A7-47838A6D7736Q29365799-48EBCF7C-24D7-4D64-B64E-823373736D47Q33569555-F91983D5-A5AB-453A-87FC-89C9068CD9CEQ33890011-8D2E916E-E0E6-49E9-A4EF-EA48D15D44A9Q34137308-0154E03F-6376-46CD-881F-80AB90105D25Q34600988-C8916D97-D184-4BA2-9E4A-5A7974A37DBFQ34773596-2BB05269-6939-4543-BC1B-2AA7EB125FD0Q35006090-CA67BCB2-2F24-4897-BD1E-7FC0E08003F2Q35116101-224B55FF-9E78-4C4B-A246-8987BB901260Q35535626-185D7F1E-488E-4FB7-9B93-419B4951FA16Q35591846-983D1505-71E9-4BB9-81E1-162AFEC6618DQ35680970-85362CA2-43A7-455E-A569-646BFE0539EBQ35767564-3EBD2EE7-495A-4EE6-9355-F55D1151B55DQ36203447-3FF0A383-5A34-418C-B8D3-8D6337351AA9Q37089336-EB32637B-EA32-4EA4-893F-158702393455Q37172342-CC0AF459-C3CD-487F-91AC-17324868CBCDQ37705215-767BA891-60E0-4135-99D2-345CA430D699Q38156841-60166848-4618-40C3-862E-1CC8834BA9C2Q38172045-ED061ACE-5123-43BD-AEE1-D7EAB7C4EC42Q38538107-EB9C5EFB-7E01-41EB-A7C7-02A6B9CC9F27Q39118758-3CA8F639-F76F-4EC7-ADAA-4B6A88EEFEEDQ41606546-7D003D9E-BD6D-44A1-A97F-4FEBD4C44448Q41828356-4186806F-2308-4A6A-BD8C-2453FE54431CQ42150934-1B70E0D2-4806-4B6A-A49C-07882FC29413Q52589518-DD4F926C-EE03-400E-9555-5CA74DDB966FQ54350964-0F82525A-2B07-4B00-B8FD-EED50CF4F49EQ57050439-1BC319FD-C22C-4D78-B354-92E8EEBB4A44Q58005133-E8544283-CE9C-4A8E-9452-035F6A333B1E
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Use of hepadnavirus core proteins as vaccine platforms.
@en
Use of hepadnavirus core proteins as vaccine platforms.
@nl
type
label
Use of hepadnavirus core proteins as vaccine platforms.
@en
Use of hepadnavirus core proteins as vaccine platforms.
@nl
prefLabel
Use of hepadnavirus core proteins as vaccine platforms.
@en
Use of hepadnavirus core proteins as vaccine platforms.
@nl
P2093
P2860
P356
P1476
Use of hepadnavirus core proteins as vaccine platforms.
@en
P2093
Byung O Lee
David C Whitacre
David R Milich
P2860
P304
P356
10.1586/ERV.09.121
P577
2009-11-01T00:00:00Z